| Sector | Prev | Curr ▼ | Delta |
|---|---|---|---|
| Pharmaceuticals & Biotechnology | 58.7% | 58.7% | ● +0.0% |
| Healthcare Services | 35.4% | 35.0% | ▼ -0.3% |
| Fertilizers & Agrochemicals | 4.5% | 4.5% | ● -0.1% |
| Chemicals & Petrochemicals | 0.5% | 0.7% | ▲ +0.2% |
| Insurance | 0.6% | 0.7% | ● +0.1% |
| Sector | Prev | Curr ▼ | Delta |
|---|---|---|---|
| Pharmaceuticals & Biotechnology | 58.7% | 60.6% | ▲ +1.8% |
| Healthcare Services | 35.0% | 33.1% | ▼ -2.0% |
| Fertilizers & Agrochemicals | 4.5% | 4.0% | ▼ -0.5% |
| Personal Products | 0.0% | 1.4% | ▲ +1.4% |
| Insurance | 0.7% | 0.4% | ▼ -0.3% |
| Chemicals & Petrochemicals | 0.7% | 0.0% | ▼ -0.7% |
Comparing Apr 2026 → May 2026
| # | Stock | Sector | Weight (May 2026) |
|---|---|---|---|
| 1 | Pfizer Limited ₹22.58 Cr |
Pharmaceuticals & Biotechnology | 1.63% |
| 2 | Gillette India Limited ₹18.67 Cr |
Personal Products | 1.35% |
| 3 | Concord Biotech Limited ₹10.71 Cr |
Pharmaceuticals & Biotechnology | 0.77% |
| # | Stock | Sector | Last Weight (Apr 2026) |
|---|---|---|---|
| 1 | Tata Chemicals Limited ₹9.51 Cr |
Chemicals & Petrochemicals | 0.72% |
| 2 | Aurobindo Pharma Limited ₹9.28 Cr |
Pharmaceuticals & Biotechnology | 0.70% |
| # | Stock | Sector | Apr 2026 | May 2026 | Change |
|---|---|---|---|---|---|
| 1 | GlaxoSmithKline Pharmaceuticals Limited ₹45.25 Cr |
Pharmaceuticals & Biotechnology | 2.44% | 3.26% | +0.82% |
| 2 | Dr Agarwals Health Care Limited ₹8.08 Cr |
Healthcare Services | 0.07% | 0.58% | +0.51% |
| 3 | Apollo Hospitals Enterprise Limited ₹63.24 Cr |
Healthcare Services | 4.06% | 4.56% | +0.50% |
| 4 | Healthcare Global Enterprises Limited ₹81.36 Cr |
Healthcare Services | 5.45% | 5.87% | +0.42% |
| 5 | Rainbow Childrens Medicare Limited ₹62.71 Cr |
Healthcare Services | 4.23% | 4.52% | +0.29% |
| 6 | Dr. Reddy's Laboratories Limited ₹55.80 Cr |
Pharmaceuticals & Biotechnology | 3.73% | 4.02% | +0.29% |
| 7 | Procter & Gamble Health Limited ₹24.91 Cr |
Pharmaceuticals & Biotechnology | 1.55% | 1.80% | +0.25% |
| 8 | Jubilant Pharmova Limited ₹7.59 Cr |
Pharmaceuticals & Biotechnology | 0.36% | 0.55% | +0.19% |
| 9 | FDC Limited ₹29.38 Cr |
Pharmaceuticals & Biotechnology | 1.94% | 2.12% | +0.18% |
| 10 | Cipla Limited ₹71.84 Cr |
Pharmaceuticals & Biotechnology | 5.07% | 5.18% | +0.11% |
| # | Stock | Sector | Apr 2026 | May 2026 | Change |
|---|---|---|---|---|---|
| 1 | Metropolis Healthcare Limited ₹22.75 Cr |
Healthcare Services | 3.07% | 1.64% | -1.43% |
| 2 | Dr. Lal Path Labs Limited ₹23.32 Cr |
Healthcare Services | 2.60% | 1.68% | -0.92% |
| 3 | Vijaya Diagnostic Centre Limited ₹15.83 Cr |
Healthcare Services | 1.72% | 1.14% | -0.58% |
| 4 | Neuland Laboratories Limited ₹26.17 Cr |
Pharmaceuticals & Biotechnology | 2.41% | 1.89% | -0.52% |
| 5 | Sun Pharmaceutical Industries Limited ₹130.11 Cr |
Pharmaceuticals & Biotechnology | 9.87% | 9.38% | -0.49% |
| 6 | Max Healthcare Institute Limited ₹66.64 Cr |
Healthcare Services | 5.17% | 4.80% | -0.37% |
| 7 | PI Industries Limited ₹4.98 Cr |
Fertilizers & Agrochemicals | 0.70% | 0.36% | -0.34% |
| 8 | Corona Remedies Limited ₹6.29 Cr |
Pharmaceuticals & Biotechnology | 0.77% | 0.45% | -0.32% |
| 9 | Syngene International Limited ₹36.82 Cr |
Healthcare Services | 2.94% | 2.65% | -0.29% |
| 10 | HDFC Life Insurance Company Limited ₹5.56 Cr |
Insurance | 0.67% | 0.40% | -0.27% |
38 stocks — May 2026
| # | Stock | Sector | Cap | Weight & Value |
|---|---|---|---|---|
| 1 |
₹130.11 Cr |
Pharmaceuticals & Biotechnology |
9.38%
|
|
| 2 |
₹81.36 Cr |
Healthcare Services |
5.87%
|
|
| 3 |
₹80.40 Cr |
Pharmaceuticals & Biotechnology |
5.80%
|
|
| 4 |
₹75.07 Cr |
Pharmaceuticals & Biotechnology |
5.41%
|
|
| 5 |
₹71.84 Cr |
Pharmaceuticals & Biotechnology |
5.18%
|
|
| 6 |
₹66.64 Cr |
Healthcare Services |
4.80%
|
|
| 7 |
₹63.24 Cr |
Healthcare Services |
4.56%
|
|
| 8 |
₹62.71 Cr |
Healthcare Services |
4.52%
|
|
| 9 |
₹55.80 Cr |
Pharmaceuticals & Biotechnology |
4.02%
|
|
| 10 |
₹52.27 Cr |
Pharmaceuticals & Biotechnology |
3.77%
|
Disclaimer: Data sourced from individual AMC monthly portfolio disclosures, as mandated by SEBI/AMFI. While we strive for accuracy, errors in parsing or presentation may occasionally occur. This is not investment advice. Please consult a SEBI-registered investment adviser before making any investment decisions.
Found a discrepancy or have feedback? Contact Us — we read every message personally.